Nektar Therapeutics

Novartis Vaccines & Diagnostics, Gmbh

Kosan Biosciences Incorporated

Alison Hannah

Timothy D Machajewski

Robert G Johnson, Jr

Eric Harwood

Michael A Eldon

Peter E Haroldsen

Carla C Heise

Shuguang Zhu

Ute Hoch

Xiao Shang

Yiqing Zhou

Emil Samara

Yen Lin Chia

Jayesh Vora

Gillian F Cropp

J Michael Sherrill

Provided is a method of treating an individual suffering from a cancer such as breast cancer by administering to the individual a long-acting topoisomerase I inhibitor such as SN-38 or irinotecan, and correlating the level of at least one tumor marker such as CA27.29 in the individual with response of the cancer to treatment with the long-acting topoisomerase I inhibitor, to thereby provide a method for predicting and assessing the therapeutic efficacy of the treatment.

Method for assessing and predicting efficacy of breast cancer treatment with a long-acting topoisomerase I inhibitor

Methods of treating cancer using 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one are provided. In particular, the methods are effective for the treatment of solid tumors or leukemias, including prostate, colorectal, breast, multiple myeloma, pancreatic, small cell carcinoma, acute myelogenous leukemia, chronic myelogenous leukemia, or myelo-proliferative disease. Further provided are methods of measuring the amount of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one and determining a metabolic profile therefore.

Methods of treating cancer and related methods

A method for treating multiple myeloma in a subject by administering 17-allylamino-17-demethoxy-geldanamycin or 17-amino geldanamycin, or a prodrug of either 17-AAG or 17-AG, to the subject.

Method of treating multiple myeloma using 17-AAG or 17-AG or a prodrug of either

Growing community of inventors

Sebastopol, CA, United States of America

Alison Hannah